

RECEIVED
SECRETARY OF THE SENATE
04 AUG 12 PM 2:20

| | |
|---|--|
| Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 | Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 |
|---|--|

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

| | | | |
|---|-----------------------------|---|----------------------------|
| 1. Registrant Name Aventis Pharmaceuticals (formerly known as Aventis Pharmaceuticals Inc.) | | | |
| 2. Address <input type="checkbox"/> Check if different than previously reported 801 Pennsylvania Avenue NW - Suite 725 | | | |
| 3. Principal Place of Business (if different from line 2) Washington DC 20004 City: State/zip (or Country) | | | |
| 4. Contact Name Ann Taylor | Telephone (202) 898-3183 | E-mail (optional) ann.taylor@aventis.com | 5. Senate ID # 56838-12 |
| 7. Client Name <input checked="" type="checkbox"/> Self | | | 6. House ID # 35186000 |

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____

11. No Lobbyir

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

| | |
|---|--|
| <p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p> | <p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ <u>1,570,000</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 603 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code</p> |
|---|--|

Signature _____

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

LD-2 (REV. 4/03)

PAGE 1

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

H.R.1 "Medicare Drug Benefit and Modernization Act of 2003"
S.1 "Medicare Drug Benefit and Modernization Act of 2003"
H.R.1 "Medicare Prescription Drug, Improvement and Modernization Act of 2003"
H.R.1 "Medicare Prescription Drug, Improvement and Modernization Act of 2003 Conference Agreement"

All provisions.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|---------------|---|
| Judy Cook | |
| Eddie Evans | |
| Ann Taylor | |
| Richard Hodge | |
| | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmace part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that essential pharmaceutical benefit cover available to the Medicare population.

Signature _____ Date _____

Printed Name and Title _____

Form LD-2 (Rec. 4/03)

Page 2

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Discussions with the Centers for Medicaid and Medicare Services (CMS) on implementation of the Medicare Modernization Act.

17. House(s) of Congress and Federal agencies contacted Check if None

Centers for Medicaid and Medicare Services, Department of Health and Human Services.

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|---------------|---|
| Judy Cook | |
| Eddie Evans | |
| Ann Taylor | |
| Richard Hodge | |
| | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmace part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that essential pharmaceutical benefit cover available to the Medicare population.

Signature _____ Date _____

Registrant Name Aventis Pharmaceuticals Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

H.R. 2673 "Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2004"
S. 1427 "Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2004"
All provisions relating to reimportation.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|---------------|---|
| Judy Cook | |
| Ann Taylor | |
| Richard Hodge | |
| | |
| | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmace part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that the safety of U.S. pharmaceuticals are for all Americans.

Signature _____ Date _____

Printed Name and Title _____

Form LD-2 (Rec. 4/03)

Page 4

Registrant Name Aventis Pharmaceuticals Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues

Organization for Economic Cooperation and Development (OECD) price control issues

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|-----------|---|
| Judy Cook | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmace part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that Aventis Pharmaceuticals is not subject price restraints.

Signature _____ Date _____

Printed Name and Title _____

Form LD-2 (Rec. 4/03)

Page 5

Registrant Name Aventis Pharmaceuticals Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R. 2427 "Pharmaceutical Market Access Act of 2003"

All provisions

17. House(s) of Congress and Federal agencies contacted Check if None


U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|---------------|---|
| Judy Cook | |
| Richard Hodge | |
| Ann Taylor | |
| Eddie Evans | |
| | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmace part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that the U.S. pharmaceutical industry is not to unfair price restraints and the

Signature  Date 8/12/04

